Page Image

The Uromigos

The Uromigos, Thomas Powles, MD, and Brian Rini, MD, FASCO, highlight the latest developments in genitourinary cancers. Each podcast episode features a guest expert from around the world discussing the latest data, debates, and manuscripts relevant to the practical clinical care of GU oncology patients.

ESMO

Latest Episode

Episode 361: The Role of Monotherapy AR Inhibition in Prostate Cancer
Our latest episode with special guest Bertrand Tombal of Manchester Cancer Research Centre focuses on the historic and current data of AR inhibition and monotherapy with AR blockers. The effects of enzalutamide and results of the EMBARK study are also discussed. ...
Advertisement
Advertisement

The Uromigos: Live and Unplugged 2023

Kidney Cancer Discussions

Dr. Brian Rini’s Disclosures

Research Funding to Institution: Pfizer, Hoffman-LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, Exelixis

Consulting: BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GSK, Shionogi, Eisai

Stock: PTC therapeutics

Advertisement
Advertisement
Get updates from The Uromigos straight to your inbox.